Continuous Glucose Monitoring– tag –
-
Trinity Biotech and Latch Medical Partner to Develop Precision Therapies for Metabolic Conditions Using Real-Time Biosensor Data
BioWorld International Overview Trinity Biotech plc has partnered with Latch Medical Ltd. to integrate data from Trinity's CGM+ wearable biosensor platform with Latch Medical's drug delivery technologies. The collaboration aims to develo... -
FDA Clears Dexcom’s Stelo OTC Continuous Glucose Monitor for Non-Insulin Users Aged Two and Up
Prime Therapeutics - Portal USA Overview The FDA has granted over-the-counter (OTC) marketing authorization for Dexcom's Stelo Glucose Biosensor System, expanding its use to non-insulin users aged two and older. This marks the first OTC ... -
FDA Selects Dexcom as Inaugural Participant in Digital Health Pilot to Accelerate AI-Integrated Glucose Management
Healthcare Dive USA Overview The U.S. FDA has named Dexcom as the first participant in its new digital health pilot program, designed to streamline regulatory pathways for innovative devices. This initiative will exempt certain Dexcom di... -
Trinity Biotech and Latch Medical Forge Alliance for AI-Powered Precision Intradermal Drug Delivery in Metabolic Disorders
GlobeNewswire (via Trinity Biotech plc) Ireland Overview Trinity Biotech has announced a strategic partnership with Latch Medical, integrating Trinity's AI-native CGM+ wearable biosensor platform with Latch Medical's innovative intraderm... -
Dexcom Selected as First Participant in FDA’s TEMPO Pilot Program to Advance AI-Powered Glucose Health for Early Prediabetes & T2D Intervention
Business Wire (via Dexcom Investor Relations) USA Overview Dexcom has been selected as the inaugural participant in the FDA's TEMPO (Technology-Enabled Meaningful Patient Outcomes) digital health devices pilot program, aiming to accelera... -
FDA Selects Dexcom as First Participant in ‘TEMPO’ Digital Health Pilot Program
MedTech Dive USA Overview The FDA has selected Dexcom as the first participant in its new Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program. This pilot will enable Dexcom to implement an AI-enabled glucose health progr... -
Medtronic Simplifies Diabetes Management with Integrated MiniMed 780G and Simplera Sync™ Sensor
Southeast Diabetes Inc. USA Overview Medtronic has introduced a state-of-the-art diabetes management solution, pairing its MiniMed 780G insulin pump system with the Simplera Sync™ sensor. Simplera Sync™ is an all-in-one, disposable conti... -
Withings Introduces Abbott’s Lingo Biosensor for Non-Invasive Glucose Management, Targeting 70-140 mg/dL Range
Withings France Overview Withings introduces Abbott's Lingo as a non-invasive continuous glucose monitor (CGM) biosensor. Lingo painlessly attaches to the upper arm, streaming real-time glucose data to the Lingo app. This allows users to... -
AI-Native Biosensors Fuel Precision Drug Delivery: Trinity Biotech and Latch Medical Target Diabetes, Obesity
GlobeNewswire (Trinity Biotech) Ireland Overview Trinity Biotech and Latch Medical have formed a strategic partnership to revolutionize diabetes and obesity treatment. The collaboration integrates Trinity Biotech's AI-native CGM+ wearabl... -
RT-CGM Reduces Inpatient and Emergency Department Encounters, Cutting Healthcare Costs for Non-Insulin-Treated Type 2 Diabetes Patients
PubMed USA Overview A retrospective study using US administrative claims data reveals that real-time continuous glucose monitoring (RT-CGM) significantly reduces healthcare resource utilization and associated medical costs among non-insu...
